NeOnc Technologies Gets FDA Nod To Expand NEO100-01™ Phase 2a Trial
NeOnc Technologies Holdings, Inc., a clinical-stage biotechnology company, has received FDA approval to expand its NEO100-01™ Phase 2a clinical trial to include patients with Recurrent Grade III Astrocytoma exhibiting IDH1 mutation. This approval follows positive results from Phase I and preliminary Phase IIa studies, demonstrating increased survivability rates in patients with the IDH1 marker. The expanded trial now includes patients with Grade III Astrocytoma, in addition to those with Grade IV, allowing NeOnc to explore treatment efficacy in a younger patient population.
NeOnc's NEO™ platform, which has shown promising results in overcoming the blood-brain barrier, continues to advance with multiple ongoing clinical studies. The company's efforts aim to develop effective, less invasive treatments for brain cancer and other central nervous system disorders. NeOnc's CEO, Dr. Thomas Chen, emphasizes the significance of this trial expansion in enhancing their innovative drug delivery methods and offering new hope to patients with limited treatment options.

Comments
Post a Comment